HIV

Causes of death after early ART in infants living with HIV from 3 sub-Saharan African countries

2024

Authors: Tagarro A, Fernández-Luis S, Dominguez-Rodriguez S, Ballesteros A, Kuhn L, Cotton FM, Giaquinto C, Rossi P, Spyer M, Otwombe K, Behuhuma O, Vaz P, Foster C, Rojo P,

Read More

An efficient envelope genotypic assay to identify bNab susceptibility in infants with HIV

2024

Authors: Delaney EK, Kearney FM, Bester AP, Coetzee N, Engelbrecht S, Giaquinto C, Rossi P, Barnabas LS, Spyer JM, Litcherfeld M, Tagarro A, Lombard C, Cotton FM, Zyl vUG and EPIICAL Consortium

Presented at: CROI 2024

Read More

1 in 5 sub-Saharan infants switches from undetectable to detectable HIV viral load during follow-up  

2024

Authors: Fernández-Luis S, Dominguez-Rodriguez S, Kuhn L, Cotton M, Giaquinto C, Rossi P, Rensburg JVA, Violari A, Lain GM, Lopez-Varela E, Sylla M, Amugue P, Rojo P, Tagarro A for EPIICAL Consortium

Presented at: CROI 2024

Read More

Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023

2024

Authors: Ambrosioni J, Levi L, Alagaratnam J, Van Bremen K, Mastrangelo A, Waalewijn H, Molina JM, Guaraldi G, Winston A, Boesecke C, Cinque P, Bamford A, Calmy A,

Simultaneous pharmacokinetic modeling of unbound and total darunavir with ritonavir in adolescents: a substudy of the SMILE trial

2023

Authors: Abdalla S, Compagnucci A, Riault Y, Chan KM, Bamford A, Nolan A, Ramos TJ, Constant V, Nguyen T, Zheng Y, Tréluyer J, Froelicher-Bournaud L, Neveux N, Saidi Y,

Pregnancy and neonatal outcomes following prenatal exposure to dolutegravir: the DOLOMITE EPPICC study

2023

Authors: Thorne C, Aebi-Popp K, Ene L, Floridia M, Gamell A, Illan M, Peters H, Samarina A, Fernandes G, Sconza R, Ragone L, Giaquinto C, Vannappagari V

Presented at: EACS 2023

Read more

What explains the poor contraction of the viral load during paediatric HIV infection?

2023

Authors: Schröter J & De Boer R

Published in: Journal of Theoretical Biology 2023

Effect of dolutegravir on folate, vitamin B12 and mean corpuscular volume levels among children and adolescents with HIV: a sub-study of the ODYSSEY randomized controlled trial 

2023

Authors: Barlow-Mosha L.N., Ahimbisibwe G.M., Chappell E., Amuge P.M., Nanduudu A., Kaudha E., Amukele T., Balamusani D., Kafufu B., Nimwesiga A., Kataike H., Namwanje R., Kasangaki G., Mulindwa A.,

Novel Approaches to Postnatal Prophylaxis to Eliminate Vertical Transmission of HIV

2023

Authors: Ruel T, Penazzato M, Zech JM, Archary M, Cressey TR, Goga A, Harwell J, Landovitz RJ, Lain MG, Lallemant M, Namusoke-Magongo E, Mukui I, Permar SR, Prendergast AJ,

The Smooth Away From Expected (SAFE) non-inferiority frontier: theory and implementation with an application to the D3 trial

2023

Authors: Quartagno, M, Chan, M, Turkova, A et al.

Published in: Trials

Sensitive HIV-1 DNA Pol Next-Generation Sequencing for the Characterisation of Archived Antiretroviral Drug Resistance

2023

Authors: Botha JC, Byott M, Spyer MJ, Grant PR, Gärtner K, Chen WX, Burton J, Bamford A, Waters LJ, Giaquinto C, et al.

Published in: Viruses

Virological suppression and weight gain in children in Europe on dolutegravir compared to protease inhibitors: a propensity score analysis 

2023

Presented by: Siobhan Crichton 

Presented at: International Workshop on HIV and Pediatrics

Read more

Uptake of integrase inhibitors and virological response in children living with HIV in Europe & Thailand from 2010 to 2020  

2023

Presented by: Jeannie Collins

Presented at: IAS and International Workshop on HIV and Pediatrics

Read more

Uptake and outcomes of tenofovir alafenamide fumarate (TAF) –based therapy in children and young people living with HIV (CLWHIV) in the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC)

2023

Presented by: Siobhan Crichton

Presented at: IAS and International Workshop on HIV and Pediatrics

Read more

Impact of COVID-19 pandemic on HIV viral load testing in paediatric HIV clinics in the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC)  

2023

Presented by: Siobhan Crichton

Presented at: IAS and International Workshop on HIV and Pediatrics

Read more

Incidence and severity of SARS-CoV-2 infection in children and young people with HIV in Europe

2023

Authors: Chappell E, Bamford A, Sanchez AB, Goetghebuer T, Marques L, Navér L, Noguera-Julian A, Talarek E, Plotnikova Y, Samarina A, Ene L, Spoulou V, Collins IJ,

Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV – Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial

2023

Authors: Compagnucci A, Chan KM, Saïdi Y, Cressey RT, Bamford A, Riault Y, Coelho A, Nolan A, Chalermpantmetagul S, Morkunaite G, Amuge P, Musiime V, Violari V, Cotton M,

Optimizing the World Health Organization algorithm for HIV vertical transmission risk assessment by adding maternal self-reported antiretroviral therapy adherence

2023

Authors: Fernández-Luis S, Lain MG, Serna-Pascual M, Domínguez-Rodríguez S, Kuhn L, Liberty A, Barnabas S, Lopez-Varela E, Otwombe K, Danaviah S, Nastouli E, Palma P, Cotugno N, Spyer M,

Determinants of B-Cell Compartment Hyperactivation in European Adolescents Living With Perinatally Acquired HIV-1 After Over 10 Years of Suppressive Therapy

2023

Authors: Ruggiero A, Pascucci GR, Cotugno N, Domínguez-Rodríguez S, Rinaldi S, Tagarro A, Rojo P, Foster C, Bamford A, De Rossi A, Nastouli E, Klein N, Morrocchi E,

Machine learning outperformed logistic regression classification even with limit sample size: A model to predict pediatric HIV mortality and clinical progression to AIDS

2023

Authors: Domínguez-Rodríguez S, Serna-Pascual M, Oletto A, Barnabas S, Zuidewind P, Dobbels E, Danaviah S, Behuhuma O, Lain MG, Vaz P, Fernández-Luis S, Nhampossa T, Lopez-Varela E, Otwombe K,

Clinical, Virological and Immunological Subphenotypes in a Cohort of Early Treated HIV-Infected Children

2023

Authors: Domínguez-Rodríguez S, Tagarro A, Foster C, Palma P, Cotugno N, Zicari S, Ruggiero A, de Rossi A, Dalzini A, Pahwa S, Rinaldi S, Nastouli E, Marcelin AG,

Mortality linked to higher inflammation in kids with perinatal HIV

2023

Speaker: Morrocchi E

Presented at: CROI 2023

Read more

SARS-COV-2 in children & adolescents living with HIV in Europe & South Africa

2023

Authors: Jackson C, Crichton S, Bamford A, Berzosa A, Gilmour K, Goetghebuer T,  Johnson SM, Judd A, Noguera-Julian A, Le Prevost M, Spoulou V, Sturgeon K,  VolokhamA, Zar HJ,

Read more

Outcomes of etravirine-based antiretroviral treatment in treatment-experienced children and adolescents living with HIV in Europe and Thailand

2022

Authors: European Pregnancy And Paediatric Infections Cohort Collaboration Eppicc, Lyons A, Thompson L, Chappell E, Ene L, Galli L, Goetghebuer T, Jourdain G, Noguera-Julian A, Kahlert CR, Königs C,

Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

2022

Authors: Amuge P, Lugemwa A, Wynne B, Mujuru AH, Violari A, Kityo MC, Archary M, Variava E, White E, Turner MR, Shakeshaft C, Ali S, Nathoo JK, Atwine L,

Probability of AIDS and non-AIDS-related mortality of early-treated children living with HIV-1

2022

Authors: Bréhin,  Tagarro A,  Domínguez-Rodríguez S,  Kuhn L,  Nhampossa T,  Otwombe K,  Janse van Rensburg A,  Klein N,  Lain MN,  Maiga AI,  Giaquinto C,  Rossi P, Rojo P,

Read more

Joint evolution of CD4 and viral load trajectories over 2 years in an early-treated pediatric African cohort

2022

Authors: Dominguez Rodriguez S, Ballesteros Á, Kuhn L, Nhampossa T, Otwombe K, Shaun Barnabas S,  Klein N, Lain M.G, Giaquinto C,  Rossi P, Rojo P, Tagarro A, EPIICAL Consortium

Presented at: AIDS 2022

Read more

Healthy dynamics of CD4 T cells may drive HIV resurgence in perinatally-infected infants on antiretroviral therapy

2022

Authors: Sinead E. Morris, Renate Strehlau, Stephanie Shiau, Elaine J. Abrams, Caroline T. Tiemessen, Louise Kuhn, Andrew J. Yates on behalf of the EPIICAL consortium and LEOPARD study teams

Published in: Plos Pathogens

Incidence of SARS-CoV-2 infection and clinical characteristics in children and young people living with HIV in Europe

2022

Authors: Chappell E, Bamford A, Berzosa Sanchez A, Goetghebuer T, Marques L, Naver L, NogueraJulian A, Talarek E, Plotnikova Y, Samarina A, Ene L, Spolou V, Collins I

Presented at: International Workshop on HIV & Pediatrics 2022

Read more

Population pharmacokinetics of unbound and total plasma dolutegravir concentrations in children ≥ 12 years old: A pharmacokinetic sub-study of the SMILE trial-PENTA17-ANRS 152

2022

Authors: Abdalla S, Compagnucci A, Riault Y, Cressey T, Saidi Y, Chan M, Coelho A, Nolan A, Chalermpantmetagul S, Amuge P, Musiime V, Violari A, Cotton M, Volokha A,

Read more

Voluntary Consent to Research on HIV-infected Children in the CHAPAS-4 and ODYSSEY HIV Clinical Trials

2022

Authors: Makumbi S, Bajunirwe F, Ford D, Turkova A, Lugemwa A, Musiime V, Gibb D, Tamwesigire K.I

Presented at: International Workshop on HIV & Pediatrics 2022

Read More

What babies need: accelerating access to current and novel antiretroviral drugs in neonates through pharmacokinetic studies

2022

Authors:Jacobs TG, Schouwenburg S, Penazzato M, Archary M, Ruel TD, van den Anker J, Burger DM, Cressey TR, Abrams EJ, Lyall H, Bekker A, Colbers A; Penta Clinical Pharmacology Working Group;

Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

2022

Authors: Turkova A, Waalewijn H, Chan M, Bollen P, Bwakura-Dangarembizi M, Kekitiinwa A, Cotton M, Lugemwa A, Variava E, Ahimbisibwe MG, Srirompotong U, Mumbiro V,Amuge P, Zuidewind P,

HIV HGM biobank as a research platform for paediatric infectious diseases and COVID-19 pandemic

2022

Authors: Irene C, Elba M, Jiménez JL, Mellado MJ, Muñoz-Fernández MÁ

Published in: AIDS Research and Therapy

miRNA Profile Based on ART Delay in Vertically Infected HIV-1 Youths Is Associated With Inflammatory Biomarkers and Activation and Maturation Immune Levels

2022

Authors: Tarancon-Diez L, Consuegra I, Vazquez-Alejo E, Ramos-Ruiz R, Ramos JT, Navarro ML, Muñoz-Fernández MÁ

Published in: Frontiers in immunology

Determinants of B-Cell Compartment Hyperactivation in European Adolescents Living With Perinatally Acquired HIV-1 After Over 10 Years of Suppressive Therapy

2022

Authors: Ruggiero A, Pascucci G.R, Cotugno N, Domínguez-Rodríguez S, Rinaldi S, Tagarro A, Rojo P, Foster C, Bamford A, De Rossi A, Nastouli E, Klein N, Morrocchi E,

The subphenotypes of early-treated children living with HIV-1

2022

Authors: S Domínguez-Rodríguez, A Tagarro, C Foster, P Palma, N Cotugno, AD Rossi, A Dalzini, SG. Pahwa, E Nastouli, K Gärtner, AG Marcelin, P Rossi, C Giaquinto, P Rojo

Presented at: CROI 2022

Read more

2-year outcome of early treated infants in Sub-Saharan Africa

2022

Authors: A Tagarro, S Domínguez-Rodríguez, L Kuhn, T Nhampossa, K Otwombe, AJv Rensburg, N Klein, MG Lain, AI. Maiga, C Brehin, C Giaquinto, P Rossi, P Rojo

Presented at: CROI 2022

Read more

Birth outcomes following prenatal exposure to dolutegravir: the DOLOMITE-EPPICC study

2022

Authors: C Thorne, K Aebi-Popp, L Ene, M Floridia, AM Gamell, M Illan, H Peters, A Samarina, L Ragone, C Giaquinto, V Vannappagari

Presented at: CROI 2022

Read more

Borrowing information across patient subgroups in clinical trials, with application to a paediatric trial

2022

Authors: R.M. Turner, A Turkova, C.L. Moore, A Bamford, M Archary, L.N. Barlow-Mosha, M.F. Cotton, T.R. Cressey, E Kaudha, A Lugemwa, H Lyall, H.A. Mujuru, V Mulenga, V Musiime,

Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

2022

Authors: H Waalewijn, M.K Chan, P.D.J Bollen, H.A Mujuru, S Makumbi, A.R Kekitiinwa, E Kaudha, T Sarfati, G Musoro, A Nanduudu, A Lugemwa, P Amuge, C.L Moore, P Rojo,

Treatment and monitoring of children and adolescents with hepatitis C in Russia: Results from a multi-centre survey on policy and practice

2022

Authors: F Malik, V Chulanov, N Pimenov, A Fomicheva, R Lundin, N Levina, C Thorne, A Turkova, G Indofi

Published in: The Journal of viral elimination

Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children

2021

Authors: A Turkova, E White, HA. Mujuru, AR. Kekitiinwa, CM. Kityo, A Violari, A Lugemwa, TR. Cressey, P Musoke, E Variava, MF. Cotton, M Archary, et al for the ODYSSEY Trial Team

Published in: New England Journal of Medicine

Size of HIV-1 reservoir is associated with telomere shortening and immunosenescence in early-treated European children with perinatally acquired HIV-1

2021

Authors: A Dalzini, G Ballin, S Dominguez-Rodriguez, P Rojo , M.R Petrara, C Foster, N Cotugno, A Ruggiero, E Nastouli, N Klein, S Rinaldi, S Pahwa, P Rossi,

Dolutegravir-based ART is superior to standard of care ART in young children <14kg living with HIV

2021

Authors: Kaudha E on behalf of the ODYSSEY trial

Presented at: PEPFAR Uganda Science Summit

Read more

Diaskin and tuberculin skin test as tuberculosis diagnostics in Russian children: comparative observational study

2021

Authors: Fritschi N, Gureva T, Eliseev P, Crichton S ,Intira Jeannie Collins IJ, Turkova T, Mariandyshev A, Ritz N

Presented at: The 52nd Union World Conference On Lung Health 2021

View poster

Read more

Characterisation of the HIV proviral and inducible reservoir in well- suppressed children on long-term ART

2021

Authors: Gärtner K, Byott M, Heaney J, Pagliuzza A, Spyer M.J Frampton D, Rossi A.D, Palmas P, Giaquinto C, Conejo P.R, Foster C,  Rossi P, Klein N, Chomont N,

Read more

Dolutegravir-based ART is superior to NNRTI- and PI-based ART in infants, children and adolescents living with HIV (combined results of the main trial and the ‘under 14kg’ cohort)

2021

Authors: Anna Turkova on behalf of the ODYSSEY trial team

Presented at: CHIVA 2021

Read more

Virological failures and genotypic resistance in children and adolescents randomised to dolutegravir-based ART vs. standard-of-care in the main ODYSSEY trial (≥14kg)

2021

Authors: White E and Kityo C on behalf of the ODYSSEY trial team

Presented at: CHIVA 2021

Read More

No age-related difference in dolutegravir metabolic glucuronidation ratio in children between 3 months and 18 years old in the ODYSSEY trial

2021

Authors: T.G Jacobs, A. Colbers, H. Waalewijn, P. Amuge, D. Bbuye, E. Kaudha, A. Nanduudu, S. Makumbi, L. Atwine, S. Mudzingwa, K. Nathoo, J. Hakim, A. Liberty, A.J. Van Rensburg,

123456789